Lubrication Behavior of Fullerene-Coated Nanoparticles on Rough Surfaces by Guangchao Han (1453198)

Lubrication Behavior of Fullerene-Coated Nanoparticles on Rough Surfaces by Guangchao Han (1453198)

Lubrication Behavior of Fullerene-Coated Nanoparticles on Rough Surfaces by Guangchao Han (1453198)

Lubrication Behavior of Fullerene-Coated Nanoparticles on Rough Surfaces by Guangchao Han (1453198)

Mean scores of IB-DE, IH-DE, and IB-DE items in Sample 1 and Sample 2 as well as women and men across the samples. by Aistė Ambrasė (22505574)

Poly(ionic liquid) Electrolytes for a Switchable Silver Mirror by Xiao Hou (3228048)

“…These findings were used to guide fabrication of a 50 cm² mirror dynamic window and flexible display. …”

Effects of different concentrations of propofol on the survival rate of zebrafish embryos and larvae. by Yali Ge (417371)

DataSheet5_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet2_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet3_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet1_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet6_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet4_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

Data_Sheet_1_Propofol EC50 for inducing loss of consciousness in patients under combined epidural-general anesthesia or general anesthesia alone: a randomized double-blind study.do... by Jiangling Wang (11929476)

“…</p>Conclusion<p>Concomitant epidural anesthesia reduced by 15% the EC₅₀ of predicted Ce_prop for LOC, decreased the consumptions of propofol and remifentanil during maintenance of anesthesia, and fastened recovery from anesthesia.…”

Example for a parametrically manipulated baby. by Sarah K. C. Holtfrerich (3353693)

Basic characteristics of the studies included. by Renáta Kiss-Miki (20760127)

“…Odd ratios (OR) and mean differences (MD) with 95% confidence intervals (CI) were calculated using a random-effects model. …”

List_of_studies_identified_31-JAN-2025. by Renáta Kiss-Miki (20760127)

“…Odd ratios (OR) and mean differences (MD) with 95% confidence intervals (CI) were calculated using a random-effects model. …”

Data_extraction_table_31-JAN-2025. by Renáta Kiss-Miki (20760127)

“…Odd ratios (OR) and mean differences (MD) with 95% confidence intervals (CI) were calculated using a random-effects model. …”

Fig 5 - by Hyun-Jun Kim (1561153)

C/EBPα binds five sites within the <i>Cebpa</i> +8 kb enhancer. by Lei Peng (260321)